Shares of the Sunnyvale, California-based company rose 3.3% in after-hours trading.
The medical device maker has seen consistent growth as hospitals work through a backlog of deferred procedures and expand access to minimally invasive care.
Intuitive’s da Vinci surgical robots are widely used for a range of procedures including weight-loss surgeries and treatments for digestive, bladder and heart conditions.
The volume of da Vinci procedures globally rose about 18% from a year ago in the reported quarter, the company said.
More than 80% of the instruments and accessories for the system are produced at Intuitive’s facility in Mexico. The company also operates in China and other international markets.
Intuitive expects da Vinci-assisted procedures to increase about 13% to 15% worldwide this year, compared with 18% growth in 2025.
It also expects 2026 gross profit margin between 67% and 68% of revenue, compared with 67.6% in 2025. This range includes an estimated impact from tariffs of 1.2% of revenue, plus or minus 10 basis points, the company said.
On an adjusted basis, Intuitive earned $2.53 per share for the quarter ended December 31, beating analysts’ estimates of $2.26 per share, according to data compiled by LSEG.
It reported quarterly revenue of $2.87 billion, compared with analysts’ estimates of $2.75 billion.
Source link
https://www.infinitycompliance.in/product/online-company-registration-in-india/